BackBellevue Life Sciences Acquisition Overview

Bellevue Life Sciences Acquisition Long Term Debt

Bellevue Life Sciences Acquisition's long-term debt is $280K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$281039.00
0.60% YoYΔ $1666.00 vs prior year quarter

Peer average

Loading

Bellevue Life Sciences Acquisition Long Term Debt History

Loading

Bellevue Life Sciences Acquisition vs. peers: Long Term Debt Comparison

Loading

Bellevue Life Sciences Acquisition Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellevue Life Sciences Acquisition (BLAC) FAQ

As of the most recent data (March 2026), BLAC shows a long-term debt of $280K. That compares with $280K in the prior-year period — up 0.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BLAC's long-term debt is now $280K (was $280K) — a 0.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition is outperforming or lagging.

Tracking BLAC's long-term debt over time shows whether Bellevue Life Sciences Acquisition is scaling, shrinking, or reshaping that part of the business. The current reading is $280K That compares with $280K in the prior-year period — up 0.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Bellevue Life Sciences Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $280K) with ownership activity and broader fundamentals.